Panel of ER Regulated Genes for Use in Monitoring Endocrine Therapy in Breast Cancer
AssigneeSanofi
InventorsMonsif Bouaboula, Hui Cao, Joon Sang Lee, Vasiliki Pelekanou, Maysoun Shomali
Life of this patent
Estimating the term…
Loading patent…
AssigneeSanofi
InventorsMonsif Bouaboula, Hui Cao, Joon Sang Lee, Vasiliki Pelekanou, Maysoun Shomali
Estimating the term…
The present disclosure relates to a panel of ER regulated genes and method for using the panel for monitoring the response of an individual having cancer to treatment with amcenestrant, the method comprising determining a first ER activity score from a sample from the individual at a first time point before treatment with amcenestrant using the panel, then determining a second ER activity score from a sample from the individual at a second time point following administration of amcenestrant using the panel, and comparing the first ER activity score with the second ER activity score, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of target engagement of amcenestrant.
A panel of ER regulated genes having N genes, wherein N is at least 7 and equal to or less than about 87, and wherein the N genes comprise any 2 to 21 of the following upregulated genes:
A method for monitoring the response of an individual having cancer to treatment with amcenestrant, the method comprising:
A kit comprising a set of probes for detecting expression of upregulated genes and downregulated genes;
Dependencies are inferred from the claim text.